Other languages BeiGene, Ltd. Deutsche Boerse AG

Equities

49B

KYG1146Y1017

Real-time Estimate Tradegate Other stock markets 15:35:37 19/06/2024 BST			5-day change	1st Jan Change
11.4 ^EUR	+3.64%		+0.92%	-11.29%

06-17	BeiGene, Ltd.(SHSE:688235) added to Shanghai Stock Exchange Health Care Sector Index	CI
06-14	BeiGene Says New Phase 3 Brukinsa Data Show 'Promising' Efficacy in Leukemia, Lymphoma	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

BeiGene présentera à l’EHA2024 de nouvelles données sur l’étude SEQUOIA évaluant la bithérapie BRUKINSA® plus vénétoclax dans le traitement de première intention de patients atteints de LLC/PLL à haut risque	06-15
EHA2024: BeiGene präsentiert neue Daten der SEQUOIA-Studie zu BRUKINSA® plus Venetoclax für die Erstlinienbehandlung von Hochrisiko-CLL/SLL	06-15
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024	06-14
Beijing Gene Announces Dose the First Five Patients in Its First-In-Human Phase 1 Trial to Evaluate BG-68501	06-12
Beigene Issues Shares Under Incentive Schemes	06-12
Zymeworks Says China's Health Regulator Accepts Biologics License Application for Cancer Therapy	06-10
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study	05-28
BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments	05-28
BriaCell Therapeutics Corp. Announces Clinical Supply Agreement with BeiGene, Ltd. for Bria-OTS First in Human Study	05-28
BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL	05-24
Glenmark Pharma Arm to Market Two Beigene Cancer Drugs in India	05-21
Glenmark Specialty S.A. Announces an Exclusive Marketing and Distribution Agreement with BeiGene	05-21
EHA2024: BeiGene präsentiert neues Hämatologie-Portfolio und Pipeline-Daten	05-15
BeiGene présente de nouvelles données de portefeuille et de pipeline d'hématologie à l'EHA2024	05-15
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024	05-14
BeiGene meldet Finanzergebnisse für das erste Quartal 2024 und aktuelle Geschäftsentwicklungen	05-09
Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up	05-09
BeiGene presenta los resultados financieros del primer trimestre de 2024 y actualiza sus actividades	05-09
BeiGene présente ses résultats financiers du premier trimestre 2024 et ses dernières nouvelles commerciales	05-09
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday	05-08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BeiGene, Ltd. Deutsche Boerse AG

Equities

49B

KYG1146Y1017

Other languages

Filters